BioCardia Inc. (BCDA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, BioCardia Inc. (NASDAQ: BCDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.93 (-2.26% 1D, market cap $14.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BCDA ranks #370 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M) and ATYR (aTyr Pharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).
Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $0 in revenue, -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While BCDA currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.05) and Max Pain ($0.98) forces dealer call-delta covering toward $1.89.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BioCardia Inc. (BCDA) dropped -2.26% to $0.93, trading at 17% of its 52-week range ($0.75 – $1.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced t
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BCDA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BCDA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BioCardia Inc. (BCDA) ranks #370 by composite RQD confidence (49/100, grade D) and #863 by equity capitalization ($14.0M). Within this direct 5-issuer industry benchmark cohort, BCDA leads on earnings valuation at N/A trailing P/E, while BCDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with BCDA at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCDA
ACTIVE
BioCardia Inc. | D | 49/100 | — | — | -35.0% | -2.26% | $14.0M | Benchmark Subject |
| DYAI Dyadic International Inc. | E | 33/100 | — | 24.9% | -35.0% | -8.40% | $14.5M | /dyai-vs-bcda → |
| ATYR aTyr Pharma Inc. | D | 44/100 | — | — | -35.0% | +4.56% | $13.5M | /atyr-vs-bcda → |
| PLUR Pluri Inc. | D- | 39/100 | — | 49.0% | -35.0% | -2.44% | $16.1M | /plur-vs-bcda → |
| PASG Passage Bio Inc. | D | 51/100 | — | — | -35.0% | +5.71% | $11.3M | /pasg-vs-bcda → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCardia Inc. (BCDA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.2M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (+5.7% YoY). On the balance sheet, BCDA closed FY2025 with $3.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.2M | -$7.4M | -$7.4M | $3.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$7.9M | -$7.9M | -$7.9M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.6M | -$10.0M | -$10.0M | — | — |
As of 2026-11-01, BioCardia Inc. (NASDAQ: BCDA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.93 (-2.26% 1D, market cap $14.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BCDA ranks #370 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M) and ATYR (aTyr Pharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).
Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $0 in revenue, -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BCDA last traded at $0.93 (-2.26% on volume of 49,077 shares), positioning the stock -11.43% below its 50-day simple moving average ($1.05) and -13.89% below its 200-day simple moving average ($1.08). Across its 52-week range of $0.75 to $1.80, BCDA sits at the 17.1% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).
Why BCDA Stock dropped -2.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).